Default: CNS Drugs

ISSN: 1172-7047

Journal Home

Journal Guideline

CNS Drugs Q1 Unclaimed

Adis International Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

CNS Drugs is a journal indexed in SJR in Neurology (clinical) and Psychiatry and Mental Health with an H index of 122. It has a price of 3190 €. It has an SJR impact factor of 1,485 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,485.

CNS Drugs focuses its scope in these topics and keywords: comprehensive, review, intravenous, neurobiological, neurogenic, orthostatic, pathophysiology, patients, peptide, properties, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -


3190 €

Inmediate OA


Embargoed OA

0 €

Non OA


CNS Drugs


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)




No comments ... Be the first to comment!

Aims and Scope

comprehensive, review, intravenous, neurobiological, neurogenic, orthostatic, pathophysiology, patients, peptide, properties, receptorsefficacy, reviewpregabalin, reviewmanagement, reviewmedication, safety, status, supine, symptoms, systematic, disorder, adherence, alcohol, antidepressant, bipolar, cannabinoid, cgrp, clinical, complicating, critical, ketamine, drug, effects, efficacy, epilepticus, esketamine, generelated, headachecns, hypertension,

Best articles by citations

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

View more

Clinical Implications of CNS Penetration of Antiretroviral Drugs

View more

Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions

View more

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

View more


View more

Comment on: "Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence"

View more

Venous Thromboembolism in Recipients of Antipsychotics

View more

Stimulation of the Nervous System for the Management of Seizures

View more

Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

View more

Amyotrophic Lateral Sclerosis

View more

Efficacy and Safety of Intravenous Valproate for Status Epilepticus: A Systematic Review

View more

Treatment of Epilepsy in Women of Childbearing Potential

View more

Eslicarbazepine Acetate

View more

Discontinuation Syndrome Associated with Paroxetine in Depressed Patients

View more

Emergency and Critical Care Management of Acute Ischaemic Stroke

View more

Treatment of Partial Seizures in Childhood

View more

New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability

View more

Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

View more

Management of Psychiatric Comorbidity in Anorexia Nervosa and??Bulimia Nervosa

View more

Pharmacotherapy for Cannabis Dependence

View more

Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy

View more

Pregabalin in the Treatment of Generalised Anxiety Disorder

View more

Weight Regain after Discontinuation of Topiramate Treatment in Patients with Migraine: a Prospective Observational Study

View more

Prevention Studies in Alzheimer's Disease: Progress Towards the Development of New Therapeutics

View more